In short
Futibatinib is an investigational drug being studied in clinical trials for the treatment of various advanced cancers. These trials aim to evaluate the safety and effectiveness of futibatinib, either alone or in combination with other therapies, in patients with specific genetic mutations or tumor types. The research focuses on cancers like cholangiocarcinoma, breast cancer, and other solid tumors with FGFR gene alterations.
At a glance
- Drug Name
- Futibatinib (also known as TAS-120)
- Drug Class
- FGFR inhibitor
- Administration
- Oral, typically 20 mg once daily
- Main Cancer Types Studied
- Cholangiocarcinoma, breast cancer, urothelial cancer, solid tumors with FGFR alterations
- Key Genetic Targets
- FGFR1, FGFR2, FGFR3, FGFR4 gene alterations
- Primary Outcomes Measured
- Overall response rate, progression-free survival, safety profile
- Common Side Effects
- Changes in phosphate levels, eye problems, fatigue, gastrointestinal issues
- Combination Therapies
- Being studied with fulvestrant, binimetinib, pembrolizumab
What is Futibatinib?
Futibatinib, also known as TAS-120 or Lytgobi, is a promising new drug being studied for the treatment of various types of cancer. It belongs to a class of medications called FGFR inhibitors, which target specific proteins involved in cancer growth.
How Futibatinib Works
Futibatinib works by blocking proteins called Fibroblast Growth Factor Receptors (FGFRs). These proteins are often overactive in certain types of cancer, causing tumor cells to grow and spread. By inhibiting these receptors, futibatinib may help slow down or stop cancer growth.
Cancers Treated with Futibatinib
Futibatinib is being studied for the treatment of several types of cancer, including:
- Cholangiocarcinoma (bile duct cancer)
- Urothelial cancer (bladder cancer)
- Non-small cell lung cancer
- Hepatocellular carcinoma (liver cancer)
- Breast cancer
- Gastric cancer (stomach cancer)
- Endometrial cancer (cancer of the uterus lining)
The drug is particularly effective in cancers with specific genetic changes in the FGFR genes, such as mutations, fusions, or amplifications.
Clinical Trials and Research
Futibatinib is currently being studied in various clinical trials to determine its effectiveness and safety. These trials include:
- Phase 1/2 studies to determine the best dose and evaluate its effectiveness in different cancer types
- Studies comparing futibatinib to other treatments or combining it with other cancer drugs
- Research on its effectiveness in specific patient groups, such as those with certain genetic mutations
Administration and Dosage
Futibatinib is typically taken orally as a tablet. The most common dosage being studied is 20 mg once daily. However, the exact dosage may vary depending on the specific study or patient needs. It's usually given in cycles, with each cycle lasting 21 or 28 days.
Side Effects and Safety
As with any medication, futibatinib can cause side effects. Common side effects being monitored in clinical trials include:
- Increased phosphorus levels in the blood
- Diarrhea
- Fatigue
- Dry mouth
- Nausea
- Changes in liver function tests
Researchers are closely monitoring patients for these and other potential side effects to ensure the drug's safety.
Combination Therapies
Futibatinib is also being studied in combination with other cancer treatments to potentially enhance its effectiveness. Some notable combinations include:
- Futibatinib with pembrolizumab (an immunotherapy drug) for urothelial cancer and liver cancer
- Futibatinib with binimetinib (a MEK inhibitor) for advanced cancers with KRAS mutations
Future Prospects
Futibatinib shows promise in treating various types of cancer, especially those with specific genetic alterations. Ongoing research aims to:
- Determine which patients are most likely to benefit from the treatment
- Explore its effectiveness in different cancer types and stages
- Investigate potential combinations with other cancer therapies
- Assess long-term safety and efficacy
As research continues, futibatinib may become an important treatment option for patients with certain types of cancer, particularly those with FGFR gene alterations.